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Abstract
Background Digital health provides solutions that capture patient-reported outcomes (PROs) and allows symptom monitoring
and patient management. Digital therapeutics is the provision to patients of evidence-based therapeutic interventions through
software applications aimed at prevention, monitoring, management, and treatment of symptoms and diseases or for treatment
optimization. The digital health solutions collecting PROs address many unmet needs, including access to care and reassurance,
increase in adherence and treatment efficacy, and decrease in hospitalizations. With current developments in oncology including
increased availability of oral drugs and reduced availability of healthcare professionals, these solutions offer an innovative
approach to optimize healthcare resource utilization.
Design This scoping review clarifies the role and impact of the digital health solutions in oncology supportive care, with a view
of the current segmentation according to their technical features (connection to sensors, PRO collection, remote monitoring, self-
management in real time…), and identifies evidence from clinical studies published about their benefits and limitations and
drivers and barriers to adoption. A qualitative summary is presented.
Results Sixty-six studies were identified and included in the qualitative synthesis. Studies supported the use of 38 digital health
solutions collecting ePROs and allowing remote monitoring, with benefits to patients regarding symptom reporting and man-
agement, reduction in symptom distress, decrease in unplanned hospitalizations and related costs and improved quality of life and
survival. Among those 38 solutions 21 provided patient self-management with impactful symptom support, improvement of
Keymessage Digital solutions with ePROs and self-management can be
incorporated in supportive care in oncology practice and provide benefits
to: patients, e.g., reduced symptom burden and distress, increased
symptom reporting, improved overall survival; healthcare professionals,
with targeted patient management; payors, potentially with reduced
supportive care-related costs and hospitalizations.
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QoL, usefulness and reassurance. Principal challenges are in developing and implementing digital solutions to suit most patients,
while ensuring patient compliance and adaptability for use in different healthcare systems and living environments.
Conclusions There is growing evidence that digital health collecting ePROs provide benefits to patients related to clinical and
health economic endpoints. These digital solutions can be integrated into routine supportive care in oncology practice to provide
improved patient-centered care.
Keywords Digital therapeutics . Integrative oncology . Symptom monitoring . Self-management . Patient-reported outcomes .
eHealth
Introduction
The International Agency for Research on Cancer estimated
that in 2018, there were 18.1 million new cancer cases world-
wide and 9.6 million cancer-related deaths [1]. A global sur-
veillance report suggests a trend toward increased survival [2],
with some cancers progressing to chronicity. However, the
total burden of new cancer cases is increasing, and new ther-
apies are generally more costly [3]. Additionally, more drugs
are available in oral formulations for home administration,
with reduced face-to-face surveillance by healthcare profes-
sionals (HCPs). Novel approaches for optimal patient man-
agement that allow containment of healthcare costs are urgent-
ly needed [4].
The new approaches should focus on patient-centered care
with integration of tumor-directed treatment and patient-di-
rected supportive and palliative care throughout the disease
journey [5, 6]. The goals of management are to achieve im-
provements in not only overall survival (OS) but also patient-
reported outcomes (PROs) such as quality of life (QOL) [7],
fewer emergency department visits, and self-reported im-
provements in symptoms [7, 8].
The intensive development over recent years of therapies
with novel mechanisms of action, including molecular-
targeted therapies, immuno-oncology therapies, and precision
radiation oncology, has transformed the oncology treatment
landscape [9, 10]. These advances have increased the com-
plexity of treatment (combination of therapies) and required
modifications in the patient pathway (oral treatment intake at
home versus hospitalization) to ensure quality care. The real-
world toxicity profile of novel agents may not always corre-
late with that observed in clinical trials and may result in
unanticipated toxicities [11, 12]. Increased availability of oral
therapies for home administration results in less healthcare
supervision during treatment, whereas the prolonged use of
such treatments as long-term maintenance may be associated
with the emergence of new toxicities [13]. Therefore, careful
monitoring of adverse events (AEs) during self-administration
of treatments at home is becoming essential to facilitate
prompt intervention to reduce their severity and duration.
Patients must therefore manage symptoms and treatment-
related side effects without direct medical supervision; home
administration of anticancer treatments also increases the
chance of nonadherence and administration errors by patients
[14]. With immunotherapeutic treatments, the timely identifi-
cation of toxicities is crucial since many symptoms may im-
prove with prompt intervention [15]. Additionally, a potential
shortage in oncology services and workforce linked to the
increasing cancer incidence and complexity of cancer treat-
ments [16] has highlighted the need for new strategies to en-
sure that all patients receive optimal treatment and care
throughout the continuum of disease.
Advances in digital communications and medical technol-
ogies have led to the digitalization of healthcare [17].
Increased access and uptake of such technologies among phy-
sicians and patients yields large amounts of potentially usable
data, which, in the context of electronic health records
(EHRs), forms an important part of physicians’ decision-mak-
ing. Self-reported data is extensively used in healthcare.
Patient-level data provide real-world medical information,
with opportunities for improved clinical decision-making, pa-
tient empowerment, improved health outcomes, and cost re-
ductions [18–20]. However, patient confidentiality and com-
pliance with local and global data privacy regulations need to
be ensured.
Digital health definitions with focus on digital
therapeutics
Digitalized healthcare comprises eHealth, telemedicine,
telemonitoring, and digital therapeutics (Fig. 1).
The terms digital health, telehealth, and eHealth are inter-
changeable and are defined as the provision of healthcare ser-
vices supported by telecommunications or digital technology
to improve or support healthcare services. eHealth solutions
can be part of each step of the healthcare process (i.e., preven-
tion, diagnosis, decision-making, treatment/intervention, and
follow-up).
Telemedicine represents medical services provided remote-
ly to patients by HCPs using telecommunications platforms.
Healthcare activities, such as patient evaluation, diagnosis, or
treatment, are performed by HCPs without the need for inpa-
tient consultation, although the legal status of such consulta-
tions varies according to jurisdiction [21].
Telemonitoring is the use of digital technology to frequent-
ly or continuously monitor patients’ vital signs or any other
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symptoms. The information is assessed remotely by HCPs to
inform the patient and caregivers about the actions needed for
appropriate symptom management and treatment advice.
Digital therapeutics embed algorithms based on medical
guidelines and best practices, which transform collected data
into actionable insights, with the objective to bring value to
evidence-based clinical outcomes (from clinical studies or re-
al-world evidence). They may be used alone or in conjunction
with drugs and medicinal products, medical devices, or other
therapies, to enhance and support medical treatment.
According to the risk level of the embedded algorithms, the
digital therapeutics may be classified as medical devices.
Depending on the regulatory status, they may be used on
prescription only (prescription digital therapeutics).
A further technology of relevance to the broad concept of
digitalized healthcare is artificial intelligence with capabilities
of machine learning, which may be defined as the use of
computer algorithms to make successful predictions about fu-
ture events based on past experiences [22].
From a health outcomes perspective, digital health can be
grouped into solutions connected to sensors or not and that
capture ePROs to allow patient monitoring only or those that
allow patient monitoring and symptom management by
HCPs, covering remote areas, or symptom management by
the patients themselves with or without real-time decision
support for self-management. Patients receive individualized
guidance, from a simple recommendation to call their HCP, to
a suggestion to begin a specific treatment intake.
Supportive care for cancer patients definition and
unmet needs
The Multinational Association of Supportive Care in Cancer
defines supportive care in cancer as “the prevention and
management of the adverse effects of cancer and its
treatment. This includes management of physical and psy-
chological symptoms and side effects across the continuum of
the cancer experience from diagnosis through treatment to
post-treatment care. Enhancing rehabilitation, secondary can-
cer prevention, survivorship, and end-of-life care are integral
to supportive care.”(About MASCC. mascc.org/about-mascc.
Accessed January 11, 2019). Whereas there has been
significant progress in anticancer treatment, improvements
for optimal supportive care are still needed at all stages of
the cancer treatment pathway [5]. Currently, supportive care
interventions’ assessment of patient QOL and medical
outcomes remains limited, and QOL endpoints are
insufficiently reported for clinical trials of novel therapies
[23].
A number of evidence-based supportive care guidelines
have been developed, but their implementation in routine clin-
ical practice is suboptimal and the opportunity to improve
control of symptoms is often forfeited [24]. This highlights
the need for more optimal use of guidelines, for personalized
and patient-centered care that is delivered in a timely manner.
Digital solutions present an opportunity to address certain
unmet needs in prevention or management of adverse events
in patients with cancer including (1) increased communication
between patients, providers, and their communities [18]; (2)
education of patients and caregivers; (3) integration of stan-
dard clinical assessments with PROs measured during routine
Fig. 1 Digital health definitions
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clinical practice; (4) help of patients in monitoring their re-
spective conditions [18]; (5) improved patient empowerment
and self-management; and (6) improved evidence from clini-
cal trials on the basis of PRO endpoints in studies evaluating
anticancer treatments and prospective evaluations of support-
ive care interventions and real-world efficiency of care for
cancer patients.
The objectives of the present review are to evaluate
the state of digital health solutions in oncology support-
ive care allowing collection of ePRO and focused on
symptom management and to identify benefits and
limitations.
Methods
Guidance of the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement was
followed in the conduct of this study (Fig. 2).
Search strategy
TheMEDLINEPublic Library ofMedicine (PubMed) database
and the Cochrane Library were explored from December 1,
2008, to November 30, 2018, for relevant studies using the
following search terms: (1) MEDLINE, “cancer or oncology”
AND “telehealth or eHealth”AND “symptommanagement” or
“symptom monitoring”; (2) Cochrane Library (title abstract
keywords), “cancer or oncology” AND “telehealth or
eHealth” AND “symptom”. Clinicaltrials.gov search was
performed using the following search strategy: “cancer or
oncology” (condition or disease) AND “telehealth or eHealth”
(other terms) AND “symptom” (outcomes measures).
Study eligibility criteria (inclusion/exclusion)
Screening of publication was done by 2 researchers on titles
and abstracts and then full-text to ensure eligibility to the
following criteria.
Fig. 2 PRISMA statement.
PRISMA Preferred Reporting




Inclusion criteria Adult cancer patients, all randomized con-
trolled trials (RCTs) or feasibility and pilot studies that evalu-
ated the effectiveness of telehealth or eHealth solutions in
supportive cancer care were eligible for inclusion in English
language.
Exclusion criteria Studies involving pediatric patients and
those evaluating solutions at the palliative phase were
excluded.
For results retrieved from clinicaltrials.gov, not completed
studies or studies without published results were excluded.
Retrieved studies were reviewed, and those evaluating so-
lutions at palliative latest phase of cancer were removed from
the analysis.
Outcomes of interest selected and assessed
Outcomes of interest were as follows for each digital solution
identified: description of the digital solution including PRO
for supportive care in oncology, with remote monitoring,
with/without patient automated symptoms self- management,
its benefits, limitations, drivers of and barriers to adoption;
unmet needs; PRO data including QOL outcomes; AE inci-
dence, severity, and management; emergency room (ER) ad-
missions and hospitalizations; health resource utilizations; and
survival outcomes including OS.
Data collection and analysis
Search results were critically analyzed by the authors for rel-
evance to the focus of this review. Two researchers extracted
the data. The authors analyzed systematically according to
outcomes of interests detailed above the study results to crit-
ically discuss the impact on outcomes of the various digital
solutions.
Results
A total of 206 articles have been identified through databases
searches in Medline, Cochrane, and Clinicaltrials.gov.
Twenty-four (24) additional records were provided from
other sources (manual search, cross-references). We
excluded narrative reviews (23), publications which titles
and abstracts were about pediatric population or focused on
palliative care phase of cancer (60), and other records (27) (not
completed results in clinical trials, conference abstracts, not in
English language, cross references to full-text articles).
Regarding the 120 selected articles, another 54 full-text
articles were excluded because of absence of study results,
duplicates, or design (exclusion when not a RCT nor a feasi-
bility study).
Finally, 66 full-text articles and associated clinical trials are
included in this review.
Digital health solutions in oncology
The review results outlining the status of clinical evidence
regarding digital health solutions that collect ePRO for sup-
portive care in oncology are summarized in Table 1 [7, 8,
25–86]. These 38 digital solutions can be classified into 2
main categories: the first, 17 digital solutions based on PRO
collection only, and the second, 21 digital solutions providing
also self-management. The key findings are summarized ac-
cording to outcome.
Clinical evidence for adoption of digital solutions
Clinical evidence for digital health solutions evaluated in fea-
sibility or randomized controlled studies are also summarized
in Table 1 [7, 8, 25–86].
Drivers and barriers to usage
From the patient perspective, some of the key factors identi-
fied for the uptake of the digital tools included the following:
(1) Ease of use [30, 38, 44, 51, 53, 55, 64, 80];
(2) Reassurance [28, 30, 41, 48, 49, 55, 59, 70];
(3) High usability and usefulness [37, 42, 44, 58, 62, 74];
(4) Improved communication with HCPs [27, 29, 30, 53, 58]
www.owise.uk;
(5) Correct generation of system alerts and fast response to
alerts [28, 70, 80];
(6) Patient empowerment [29, 30, 69]; and
(7) The convenience of real-time reporting of symptoms [28,
37];
One study evaluating the extent of patient use of a Web-
based intervention reported that reduction of cancer symptom
distress was a key driver of uptake, with use of the interven-
tion resulting in a significant reduction in distress score [47].
Conversely, some of the barriers for adoption encountered
by patients were as follows:
(1) Problems with technology or connectivity [48, 49, 69,
80];
(2) Limited usefulness [29, 30, 71];
(3) Lack of clarity of the language used [29, 30]; and
(4) Generation of false alerts [69].
Whereas higher education level, current employment, and
low levels of social support have been associated with uptake,
lower education level and non-working status may be barriers


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fewer studies have assessed the feasibility of digital solu-
tions from the HCP perspective. The most important reasons
for adoption reported by HCPs were the usability and useful-
ness of the tool [26, 38, 52, 58], and the most commonly
reported barrier was problemswith technology or connectivity
[31, 75].
Interestingly, while some tools were perceived as a burden
due to increased workload [28], others did not impact the
working time of HCPs [69, 85].
Impact on clinical assessment
Most studies presented ePRO data, including symptom dis-
tress and burden, pain, depression, and adherence.
A meta-analysis of 9 studies reported a statistically signif-
icant benefit for digital interventions in patients with cancer-
related fatigue, with moderate benefits also observed for QOL
and depression [45].
Several studies showed a significant reduction compared
with usual care in symptom-related distress on the basis of
measures that included Short-Form (SF)-36, Memorial
Symptom Assessment Scale (MSAS), Symptom Distress
Scale-15 (SDS-15), and Functional Assessment of Cancer
Therapy-Head & Neck Scale (FACT-HN) [36, 40, 45, 47,
50, 78, 85]. Symptom benefit was observed in conjunction
with automated home or Web-based symptom self-manage-
ment systems.
Studies also reported a reduction in depression [73, 85],
symptom severity [33, 53], pain [43, 56, 73, 77], and need
for symptom management support [40].
An RCT enrolling 766 patients with solid tumors receiving
outpatient chemotherapy demonstrated that self-reporting of
12 common cancer-related symptoms led to significant im-
provement in QOL, as measured by the EuroQol EQ-5D
Index [8].
Two studies used the European Organization for Research
and Treatment of Cancer Qualify of Life Questionnaire Core
30 (EORTC-QLQ-C30) for QOL assessment [43, 52]. One of
these used the EORTC-QLQ-C30 and the Hospital Anxiety
and Depression Scale (HADS) as an intervention, with a larg-
er proportion of patients who reported these measures to their
oncologists showing clinically meaningful improvements in
QOL compared with a control group, despite no detectable
changes in patient management [52].
An RCT evaluating the impact of an internet-based exer-
cise intervention reported significant improvement in
EORTC-QLQ-C30 scores for global health status, physical,
role, and cognitive functioning, together with improvements
in pain severity on the Brief Pain Inventory compared with
control [43].
In another study of a Web-based intervention, the addition
of self-care instructions and communication coaching to
Electronic Self-report Assessment–Cancer (ESRA-C) of
symptoms and QOL resulted in significant increase in
reporting fatigue, pain, and physical function issues.
However, differences between groups in symptom distress
reported by patient did not reach significance [46].
Finally, a report found benefit for patient QOL, including
increased symptom identification and management, and im-
proved functional status following electronic collection of
Therapy-Related Symptom Checklist for Adults (TRSC) [81].
Impact on survival
A prospective study compared survival in patients with lung
cancer who were assigned to weekly symptom self-reporting
via a Web application intervention for early detection of re-
lapse with a retrospective group of control patients [60].
Median OS was improved for the patients assigned to the
intervention compared with the historical control arm.
Survival outcomes were also reported in 2 RCTs. A single-
center trial reported that integration of ePROs into the routine
care of patients with metastatic cancer led to increased surviv-
al compared with usual care [7]. At a median follow-up of
7 years, median OS was 31.2 months (95% CI, 24.5–39.6)
in the group that provided self-report of 12 common symp-
toms, with severe or worsening symptoms triggering an email
alert and follow-up care by a nurse practitioner with escalation
as needed. In comparison, median OS in the group assigned to
usual care was 26.0 months (95% CI, 22.1–30.9; difference,
5 months; P = .03). In patients with advanced lung cancer, a
multicenter study reported that intervention involving a Web-
based follow-up algorithm to assess weekly patient symptom
self-reports compared with routine follow-up resulted in me-
dian OS of 19.0 (95% CI, 12.5-noncalculable) and
12.0 months (95% CI, 8.6–16.4), respectively (P = .001)
[61]. In addition, the performance status at first relapse was
0 to 1 for 76% of patients in the intervention arm compared
with 33% in the control arm (2-sided P < .001); anticancer
treatment was considered to be optimal in 72% and 33%,
respectively (2-sided P < .001). In the final OS analysis for
this study, median OS was 22.5 months in the intervention
group and 14.9 months in the control group (hazard ratio, 0.59
[95% CI, 0.37–0.96]; P = .03) [87].
Impact on ER admissions, hospitalizations, and healthcare
resource utilization
The effect of digital solutions on the number of ER visits,
hospital days, or utilization of healthcare resources is not com-
monly evaluated in clinical studies. Some solutions, involved
in patient monitoring providing or not providing feedback for
self-management, have been associatedwith a reduction in ER
visits, unplanned hospitalizations, and hospital days [8, 35,
73]. Additionally, use of a telehealth system for rehabilitation
of patients with head and neck cancer following chemo-/
Support Care Cancer
radiotherapy resulted in fewer and shorter appointments until
discharge compared with usual care and was accompanied by
a significant cost-reduction for patients, specifically in travel
costs [51]. On the contrary, one study using a Web-based
intervention that included review by a nurse practitioner found
no differences compared with control with respect to
healthcare resource use, including oncology-related appoint-
ments, number of physician visits, or medical tests [75]. The
effect of digital solutions on overall healthcare costs needs
further assessment [8, 35, 73, 75].
Clinical benefits and limitations of the digital
solutions for stakeholders
Benefits and limitations of introducing a patient-management
solution in oncology, according to stakeholders of digital
solutions in the healthcare system, are summarized in
Table 2 and illustrated in Fig. 3. These benefits and limitations
were identified in the selected publications and from the au-
thors experience and opinion. Lots of benefits have been iden-
tified of important impact on all stakeholders (patients, physi-
cians, caregivers, nurses, healthcare system, pharmaceutical
company), with limitations related to technical dealing, regu-
latory constraints, costs, and changes in practices.
Discussion
Although the clinical benefits of remote patient monitoring
have been demonstrated in clinical trials [7, 62], achieving
optimal supportive care requires strategies that go beyond
ePRO apps/systems. Such benefits are not obtained solely
Table 2 Benefits and limitations of digital healthcare solutions for stakeholders
Stakeholder Benefits Limitations
Patients - Promote patient-centricity
- Direct communication with HCPs
- Closer involvement in the decision-making process
- Impact on treatment-adherence
- Information from clinical visits always available
- Relevant disease- and treatment-related information always available
- Less recourse to generic Web consultation without scientific content
- Difficulty in dealing with technology
- Need for specific education and training
- Time-consuming
- Uncomfortable asking clinicians for
permission to record clinical visits
- Depersonalization
Physicians - Improved communication with patients
- Shared decision-making by involving patients in the process
- Real-world data collection in real time
- Optimal management of toxicities in real time
• Increased motivation thanks to visible improvements
- Effective time-management
• Time saving in the analyses of patients’ data
• Contact patients only when clinically relevant situations occur
- Focused supportive care
- Less healthcare resource utilization
- Difficulty in dealing with technology
- Need for specific training to ensure engagement
- Time dedicated outside of consultation hours
- Changes in the organization of HCP teams
- Difficulty in changing usual practices of
symptom management
Nurses - Effective time-management
• Time saving in the analyses of patients’ data
• Contact patients only when clinically relevant situations occur
- Increased quality of services with less healthcare resource utilization
- Improved patient-nurse communication
- Difficulty in dealing with technology
- Need for specific training to ensure engagement
- Time dedicated to educating and inform patients
and caregivers
- Additional time allocated outside patients’ visits
Caregivers - Reduced burden and anxiety
- Increased satisfaction
- Difficulty in dealing with technology
- Need for specific education and training
Healthcare system - Impact of preventive care in healthcare costs. Cost-effectiveness
benefits
• Reduction in ER visits, wait time in ER, transportation costs
• Reduction in unplanned visits and hospitalizations
• Impact on the working time of physicians, nurses, ER personnel
• Reduction in medication cost
• Prevention and treatment of AEs more consistent with guidelines
- Need for development of processes and regulations
for homologation of digital solutions by regulatory
agencies
- Formation and training of dedicated teams for
evaluation
- Delays in cost-effectiveness analyses for the
implementation of reimbursement policies,
resulting
in impeded access to patients
Pharmaceutical
industry
- Real-world data and increased knowledge of the toxicity profile of
drugs
- Development of plans for improved management of AEs
- Expedited approval of drugs when filing in combination with digital
solutions
- Additional studies with the drug + digital solution
combination needs to be performed, to generate
clinical evidence of efficacy and safety to support
filing: increased time and cost
AE adverse event, ER emergency room, HCP healthcare professional
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through the assessment of outcomes of interest but also
through appropriate management in response to assessments.
Even if benefits have been confirmed in the setting of RCTs,
there is a need to continue to evaluate ePRO efficacy and
efficiency in real-world conditions, with ongoing assurances
of data security and privacy, to provide relevant information
for optimal self-management.
Several factors need to be considered for a high-quality
symptom self-management system. Guidance from the
treating physician is critical. Electronic self-reported assess-
ment tools for cancer-related symptoms and QOL can increase
communication between patients and HCPs and promote dis-
cussion that is focused on symptoms and QOL. Digital tools
that give advice to patients on the reporting of symptoms to
HCPs have been shown to increase symptom reports by pa-
tients during visits. However, these have not been shown to
impact practitioner responses, indicating that guideline adher-
ence and commitment by the medical team is also needed. The
collection of information regarding related clinical symptoms
and the medication received requires integration with elec-
tronic real-time monitoring of symptoms into oncologists’
routine clinical practice. When real-time monitoring is used,
beneficial outcomes in terms of symptom management have
been identified [88], with the potential for further optimization
when structured patient education or practitioner-/nurse-led
symptom counseling is in place. Optimization of digital tools
requires integration with the patients’ EHRs, thereby allowing
continuity in the flow of patient-related data and the healthcare
support systems.
Digital health solutions need to be integrated into the patient
pathway and in healthcare team practices for optimal support-
ive care in oncology in line with appropriate guidelines. How
this integration is implemented is debatable, with consideration
given as to whether the digital tool is merged into current
healthcare systems in a gradual or disruptive manner. The
European Society for Medical Oncology (ESMO) has devel-
oped a Magnitude of Clinical Benefit Scale (ESMO-MCBS) to
assess the extent of the clinical benefit from new and effective
Fig. 3 Benefits and limitations of
digital solutions in the healthcare





anticancer therapies measuring improvement in survival, dis-
ease-free survival, response, grade 3–4 toxicities, and QOL
measures [89]. MCBS-based assessment of the digital tools
as part of anticancer therapies and the use of MCBS for the
development of clinical guidelines would ease this integration.
There are challenges in the development of a digital solu-
tion for supportive care of cancer patients. Setting up and
conducting clinical trials for the evaluation of digital tools is
a long process, especially because digital solutions need to be
quickly available for evaluation in real-world settings. The
principal difficulties are in developing and implementing a
solution to fit the needs of all or most patients, while achieving
the necessary patient compliance to change with the new dig-
ital tool and integrate it into care and maintaining enough
adaptability for its use in different regulatory systems and
healthcare centers. Implementation may be associated with
challenges in staff having to deal with new technologies,
accepting and adapting to changes, and the potential for
reorganization of multidisciplinary teams/treatment centers.
Maintenance of the device may also introduce complexity
since device utility is dependent on updates in accordance
with relevant guidelines, as well as drug safety information,
approval of new drugs, and the use of different drugs from the
same class. Oncologic therapy is by its nature complex, with
sequential phases, and device utility will need to reflect the use
of different antitumor regimens, including radiotherapy and
radio-chemotherapy, and combination of drugs. Uptake of
the technology may be dependent on oncologist perceptions
of patients’ willingness to adopt new technologies, as well as
the actual willingness of patient subgroups, particularly elder-
ly patients, to embrace digital solutions. Finally, digital solu-
tions should be perceived as facilitators of in-person commu-
nication between patient and practitioner.
This review offers elements for scoping digital solution
based on feasibility studies on limited level of evidence or still
limited numbers of patients evaluated on RCT.
Fig. 4 Ideal digital health solution
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Outlook for the future
Several clinical studies have already demonstrated reliability,
feasibility, and clinical value (various symptoms, QOL, and
OS) with efficacy of ePRO collection through digital solu-
tions. The ideal digital solution in the setting of supportive
care in oncology would present with the following character-
istics (Fig. 4): it would be user-friendly, intuitive, and engag-
ing to meet the immediate needs of the end-users; it would
also be efficient at processing and delivering relevant infor-
mation to provide supportive care as its principal aim. In
thinking about its place in the supportive care setting, the ideal
digital solution is not intended as a replacement for the prac-
titioner; rather, its intended value would be in providing addi-
tional information that is appropriate to the care of the patient
and the specific issues associated with their disease in real
time. This information would be sufficiently detailed but not
overcomplicated and presented in a language the patient un-
derstands in order to be accessible by the patient for effective
symptom self-management [90]. The digital solution would
maintain existing expectations regarding patient confidential-
ity and data privacy [91], cybersecurity, compliance with reg-
ulatory requirements, and being updated according to the most
recent evidence-based practice. It would be operational
throughout the entire course of the disease and for all antican-
cer treatments. Its built-in flexibility would enable adaptation
of the digital tool to all territories, institutions, and centers and
to all different care needs according to whether treatment is
delivered in the community or at a regional center, such that it
also serves patients who live in remote areas. It would be
customizable to adapt to the needs of the individual patient.
It would have a seamless connection with HCPs’ systems.
Integration with patients’ EHR would allow for rapid fol-
low-up and intervention as appropriate by HCPs in re-
sponse to system alerts triggered by patient reports of clin-
ically relevant events. It would have a high level of accep-
tance both by HCPs and patients, allowing its complete
adoption and full integration in the patient pathway and
in routine clinical practice. For digital solutions with prov-
en clinical and cost benefits, reimbursement policies would
be in place to ensure availability for implementation
through defined market access programs. Finally, the ideal
digital solution would not only provide the means for pa-
tient self-management of anticancer treatment-related
symptoms but would also provide psychosocial support
and improve QOL. Although a single system would not
be able to address all needs—treatment adherence, symp-
tom management, alignment with guidelines, medication
reminders, medical and nutritional information, resources
for social support, and coping strategies—it is important
that digital tools find common ground, with solutions of-
fered to address key challenges in the setting of supportive
care in cancer.
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